Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTC NASDAQ:IVVD NASDAQ:NGNE NASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$12.49+2.4%$11.67$9.85▼$17.15$424.39M0.28147,077 shs24,329 shsIVVDInvivyd$1.47+5.4%$1.57$0.48▼$3.07$414.30M0.712.88 million shs1.42 million shsNGNENeurogene$32.06+10.8%$22.52$12.97▼$37.27$500.78M1.69166,156 shs141,919 shsPEPGPepGen$1.71-11.7%$3.71$1.01▼$7.80$117.24M2.011.21 million shs473,611 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma+2.09%+0.25%+11.72%-1.69%-15.45%IVVDInvivyd-8.55%+0.72%+8.59%-24.46%+141.57%NGNENeurogene+7.78%+5.43%+39.87%+68.45%+91.53%PEPGPepGen+10.29%+22.15%+11.56%-60.69%+34.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$12.49+2.4%$11.67$9.85▼$17.15$424.39M0.28147,077 shs24,329 shsIVVDInvivyd$1.47+5.4%$1.57$0.48▼$3.07$414.30M0.712.88 million shs1.42 million shsNGNENeurogene$32.06+10.8%$22.52$12.97▼$37.27$500.78M1.69166,156 shs141,919 shsPEPGPepGen$1.71-11.7%$3.71$1.01▼$7.80$117.24M2.011.21 million shs473,611 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma+2.09%+0.25%+11.72%-1.69%-15.45%IVVDInvivyd-8.55%+0.72%+8.59%-24.46%+141.57%NGNENeurogene+7.78%+5.43%+39.87%+68.45%+91.53%PEPGPepGen+10.29%+22.15%+11.56%-60.69%+34.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTCBenitec Biopharma 2.57Moderate Buy$27.67121.53% UpsideIVVDInvivyd 2.33Hold$8.00446.08% UpsideNGNENeurogene 2.75Moderate Buy$67.00108.98% UpsidePEPGPepGen 2.67Moderate Buy$11.80592.08% UpsideCurrent Analyst Ratings BreakdownLatest PEPG, BNTC, NGNE, and IVVD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026IVVDInvivyd Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/28/2026NGNENeurogene GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$69.004/28/2026NGNENeurogene GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026NGNENeurogene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026BNTCBenitec Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026NGNENeurogene Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$180.003/31/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $5.003/9/2026BNTCBenitec Biopharma TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/9/2026BNTCBenitec Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.002/27/2026NGNENeurogene Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTCBenitec Biopharma$80K5,362.46N/AN/A$3.71 per share3.37IVVDInvivyd$53.43M7.75N/AN/A$1.04 per share1.41NGNENeurogene$930K538.47N/AN/A$17.10 per share1.87PEPGPepGenN/AN/AN/AN/A$2.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTCBenitec Biopharma-$37.92M-$1.14N/AN/AN/AN/A-38.92%-37.68%5/13/2026 (Estimated)IVVDInvivyd-$52.49M-$0.32N/AN/AN/A-98.25%-48.65%-34.48%5/7/2026 (Estimated)NGNENeurogene-$90.35M-$4.24N/AN/AN/AN/A-32.99%-30.39%5/7/2026 (Estimated)PEPGPepGen-$89.65M-$2.41N/AN/AN/AN/A-75.73%-60.42%5/14/2026 (Estimated)Latest PEPG, BNTC, NGNE, and IVVD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026PEPGPepGen-$0.31N/AN/AN/AN/AN/A5/13/2026Q3 2026BNTCBenitec Biopharma-$0.27N/AN/AN/A$4.55 millionN/A5/7/2026Q1 2026IVVDInvivyd-$0.08N/AN/AN/A$18.04 millionN/A5/7/2026Q1 2026NGNENeurogene-$1.2963N/AN/AN/AN/AN/A3/24/2026Q4 2025NGNENeurogene-$1.20-$1.12+$0.08-$1.12N/AN/A3/4/2026Q4 2025PEPGPepGen-$0.40-$0.27+$0.13-$0.27N/AN/A2/12/2026Q2 2026BNTCBenitec Biopharma-$0.23-$0.26-$0.03-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTCBenitec BiopharmaN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTCBenitec BiopharmaN/A67.6967.69IVVDInvivydN/A7.247.24NGNENeurogeneN/A16.5616.56PEPGPepGenN/A11.9411.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTCBenitec Biopharma52.19%IVVDInvivyd70.36%NGNENeurogene52.37%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipBNTCBenitec Biopharma4.80%IVVDInvivyd12.25%NGNENeurogene9.92%PEPGPepGen4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTCBenitec Biopharma2034.35 million32.71 millionNo DataIVVDInvivyd100282.80 million248.16 millionOptionableNGNENeurogene9015.62 million14.07 millionOptionablePEPGPepGen3069.17 million65.99 millionNot OptionablePEPG, BNTC, NGNE, and IVVD HeadlinesRecent News About These CompaniesPictet Asset Management Holding SA Purchases 871,059 Shares of PepGen, Inc. $PEPGMay 3 at 5:39 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 28, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)April 26, 2026 | theglobeandmail.comStifel Nicolaus Sticks to Its Buy Rating for PepGen Inc. (PEPG)April 26, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 16, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 14, 2026 | globenewswire.comPepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by BrokeragesApril 13, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 9, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 7, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 2, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 2, 2026 | prnewswire.comPepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some ReliefMarch 31, 2026 | seekingalpha.comPepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting DiseaseMarch 31, 2026 | biospace.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGMarch 31, 2026 | globenewswire.comPepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMarch 31, 2026 | globenewswire.comPepGen crashes after mid-stage trial data for muscle disorder therapyMarch 31, 2026 | msn.comPepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data TranscriptMarch 31, 2026 | seekingalpha.comPepGen stock tumbles 44% on disappointing trial resultsMarch 30, 2026 | za.investing.comStocks to Watch: PepGen, Phreesia, Virgin GalacticMarch 30, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026These 3 ETFs Are Suitable for Ultra-Bearish InvestorsBy Nathan Reiff | April 11, 2026PEPG, BNTC, NGNE, and IVVD Company DescriptionsBenitec Biopharma NASDAQ:BNTC$12.49 +0.29 (+2.37%) As of 12:24 PM Eastern This is a fair market value price provided by Massive. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Invivyd NASDAQ:IVVD$1.46 +0.08 (+5.40%) As of 12:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Neurogene NASDAQ:NGNE$32.06 +3.12 (+10.78%) As of 12:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.PepGen NASDAQ:PEPG$1.70 -0.23 (-11.66%) As of 12:25 PM Eastern This is a fair market value price provided by Massive. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
